Lipocalin-2 and iron trafficking in the tumor microenvironment

Pharmacological Research

Volumn 120, Issue , 2017, Pages 146-156

  Jung, Michaela ^a   Mertens, Christina ^a   Bauer, Rebekka ^a   Rehwald, Claudia ^a   Brüne, Bernhard ^a,b  

^a GOETHE UNIVERSITY   (Germany)

^b FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME   (Germany)

Author keywords

Iron; Iron chelators; Lipocalin 2; Macrophages; Siderophores; Tumor microenvironment

Indexed keywords

CD71 ANTIGEN; FERROPORTIN; GAMMA INTERFERON; GELATINASE B; GENTISIC ACID; HEPCIDIN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; SIDEROPHORE; TRANSFERRIN; UVOMORULIN; ANTINEOPLASTIC AGENT; IRON; IRON CHELATING AGENT;

BREAST CANCER; CANCER GROWTH; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE ASSOCIATION; HOMEOSTASIS; HUMAN; IRON HOMEOSTASIS; IRON METABOLISM; IRON STORAGE; IRON TRANSPORT; LYMPHOCYTE SUBPOPULATION; MACROPHAGE; MALIGNANT NEOPLASM; MOLECULAR WEIGHT; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; SURVIVAL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR DERIVED SIGNAL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR SURVIVAL; ANIMAL; DRUG EFFECTS; METABOLISM; NEOPLASM; PATHOLOGY; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; HUMANS; IRON; IRON CHELATING AGENTS; LIPOCALIN-2; MACROPHAGES; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 85017118037     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2017.03.018     Document Type: Review

References (152)

1. [1] Richardson, D.R., Kalinowski, D.S., Lau, S., Jansson, P.J., Lovejoy, D.B., Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents. Biochim. Biophys. Acta 1790:7 (2009), 702–717, 10.1016/j.bbagen.2008.04.003.
2. [2] Kukulj, S., Jaganjac, M., Boranic, M., Krizanac, S., Santic, Z., Poljak-Blazi, M., Altered iron metabolism, inflammation, transferrin receptors, and ferritin expression in non-small-cell lung cancer. Med. Oncol. 27:2 (2010), 268–277, 10.1007/s12032-009-9203-2.
3. [3] Miller, L.D., Coffman, L.G., Chou, J.W., Black, M.A., Bergh, J., D'Agostino, R. Jr., Torti, S.V., Torti, F.M., An iron regulatory gene signature predicts outcome in breast cancer. Cancer Res. 71:21 (2011), 6728–6737, 10.1158/0008-5472.CAN-11-1870.
4. [4] Xue, X., Shah, Y.M., Intestinal iron homeostasis and colon tumorigenesis. Nutrients 5:7 (2013), 2333–2351, 10.3390/nu5072333.
5. [5] Faulk, W.P., Hsi, B.L., Stevens, P.J., Transferrin and transferrin receptors in carcinoma of the breast. Lancet 2:8191 (1980), 390–392.
6. [6] Habashy, H.O., Powe, D.G., Staka, C.M., Rakha, E.A., Ball, G., Green, A.R., Aleskandarany, M., Paish, E.C., Douglas Macmillan, R., Nicholson, R.I., Ellis, I.O., Gee, J.M., Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen. Breast Cancer Res. Treat. 119:2 (2010), 283–293, 10.1007/s10549-009-0345-x.
7. [7] Brookes, M.J., Hughes, S., Turner, F.E., Reynolds, G., Sharma, N., Ismail, T., Berx, G., McKie, A.T., Hotchin, N., Anderson, G.J., Iqbal, T., Tselepis, C., Modulation of iron transport proteins in human colorectal carcinogenesis. Gut 55:10 (2006), 1449–1460, 10.1136/gut.2006.094060.
8. [8] Chekhun, S.V., Lukyanova, N.Y., Shvets, Y.V., Burlaka, A.P., Buchinska, L.G., Significance of ferritin expression in formation of malignant phenotype of human breast cancer cells. Exp. Oncol. 36:3 (2014), 179–183.
9. [9] Chekhun, V.F., Lukyanova, N.Y., Burlaka, C.A., Bezdenezhnykh, N.A., Shpyleva, S.I., Tryndyak, V.P., Beland, F.A., Pogribny, I.P., Iron metabolism disturbances in the MCF-7 human breast cancer cells with acquired resistance to doxorubicin and cisplatin. Int. J. Oncol. 43:5 (2013), 1481–1486, 10.3892/ijo.2013.2063.
10. [10] Wang, W., Deng, Z., Hatcher, H., Miller, L.D., Di, X., Tesfay, L., Sui, G., D'Agostino, R.B. Jr., Torti, F.M., Torti, S.V., IRP2 regulates breast tumor growth. Cancer Res. 74:2 (2014), 497–507, 10.1158/0008-5472.CAN-13-1224.
11. [11] Pinnix, Z.K., Miller, L.D., Wang, W., D'Agostino, R. Jr., Kute, T., Willingham, M.C., Hatcher, H., Tesfay, L., Sui, G., Di, X., Torti, S.V., Torti, F.M., Ferroportin and iron regulation in breast cancer progression and prognosis. Sci. Transl. Med., 2(43), 2010, 43ra56, 10.1126/scisignal.3001127.
12. [12] Torti, S.V., Torti, F.M., Cellular iron metabolism in prognosis and therapy of breast cancer. Crit. Rev. Oncog. 18:5 (2013), 435–448.
13. [13] Anees Ahmed, R.A., Ganvir, S.M., Hazarey, V.K., Relation of erythrocyte indices and serum iron level with clinical and histological progression of oral squamous cell carcinoma in Central India. J. Invest. Clin. Dent. 5:1 (2014), 65–71, 10.1111/jicd.12021.
14. [14] Ludwig, H., Muldur, E., Endler, G., Hubl, W., Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia. Ann. Oncol. 24:7 (2013), 1886–1892, 10.1093/annonc/mdt118.
15. [15] Tortorella, S., Karagiannis, T.C., Transferrin receptor-mediated endocytosis: a useful target for cancer therapy. J. Membr. Biol. 247:4 (2014), 291–307, 10.1007/s00232-014-9637-0.
16. [16] Gunshin, H., Mackenzie, B., Berger, U.V., Gunshin, Y., Romero, M.F., Boron, W.F., Nussberger, S., Gollan, J.L., Hediger, M.A., Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature 388:6641 (1997), 482–488, 10.1038/41343.
17. [17] Radulescu, S., Brookes, M.J., Salgueiro, P., Ridgway, R.A., McGhee, E., Anderson, K., Ford, S.J., Stones, D.H., Iqbal, T.H., Tselepis, C., Sansom, O.J., Luminal iron levels govern intestinal tumorigenesis after Apc loss in vivo. Cell Rep. 2:2 (2012), 270–282, 10.1016/j.celrep.2012.07.003.
18. [18] Jian, J., Yang, Q., Huang, X., Src regulates Tyr(20) phosphorylation of transferrin receptor-1 and potentiates breast cancer cell survival. J. Biol. Chem. 286:41 (2011), 35708–35715, 10.1074/jbc.M111.271585.
19. [19] Chacko, A.M., Li, C., Pryma, D.A., Brem, S., Coukos, G., Muzykantov, V., Targeted delivery of antibody-based therapeutic and imaging agents to CNS tumors: crossing the blood-brain barrier divide. Expert Opin. Drug Deliv. 10:7 (2013), 907–926, 10.1517/17425247.2013.808184.
20. [20] Daniels, T.R., Bernabeu, E., Rodriguez, J.A., Patel, S., Kozman, M., Chiappetta, D.A., Holler, E., Ljubimova, J.Y., Helguera, G., Penichet, M.L., The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim. Biophys. Acta 1820:3 (2012), 291–317, 10.1016/j.bbagen.2011.07.016.
21. [21] Xu, L., Huang, C.C., Huang, W., Tang, W.H., Rait, A., Yin, Y.Z., Cruz, I., Xiang, L.M., Pirollo, K.F., Chang, E.H., Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes. Mol. Cancer Ther. 1:5 (2002), 337–346.
22. [22] Sahoo, S.K., Labhasetwar, V., Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. Mol. Pharm. 2:5 (2005), 373–383, 10.1021/mp050032z.
23. [23] Shpyleva, S.I., Tryndyak, V.P., Kovalchuk, O., Starlard-Davenport, A., Chekhun, V.F., Beland, F.A., Pogribny, I.P., Role of ferritin alterations in human breast cancer cells. Breast Cancer Res. Treat. 126:1 (2011), 63–71, 10.1007/s10549-010-0849-4.
24. [24] Orlandi, R., De Bortoli, M., Ciniselli, C.M., Vaghi, E., Caccia, D., Garrisi, V., Pizzamiglio, S., Veneroni, S., Bonini, C., Agresti, R., Daidone, M.G., Morelli, D., Camaschella, C., Verderio, P., Bongarzone, I., Hepcidin and ferritin blood level as noninvasive tools for predicting breast cancer. Ann. Oncol. 25:2 (2014), 352–357, 10.1093/annonc/mdt490.
25. [25] Weinstein, R.E., Bond, B.H., Silberberg, B.K., Tissue ferritin concentration in carcinoma of the breast. Cancer 50:11 (1982), 2406–2409, 10.1002/1097-0142(19821201)50:11<2406:AID-CNCR2820501127>3.0.CO;2-S.
26. [26] Weinstein, R.E., Bond, B.H., Silberberg, B.K., Vaughn, C.B., Subbaiah, P., Pieper, D.R., Tissue ferritin concentration and prognosis in carcinoma of the breast. Breast Cancer Res. Treat. 14:3 (1989), 349–353, 10.1007/bf01806307.
27. [27] Jézéquel, P., Campion, L., Spyratos, F., Loussouarn, D., Campone, M., Guérin-Charbonnel, C., Joalland, M.P., André, J., Descotes, F., Grenot, C., Roy, P., Carlioz, A., Martin, P.M., Chassevent, A., Jourdan, M.L., Ricolleau, G., Validation of tumor-associated macrophage ferritin light chain as a prognostic biomarker in node-negative breast cancer tumors: A multicentric 2004 national PHRC study. Int. J. Cancer 131:2 (2012), 426–437, 10.1002/ijc.26397.
28. [28] Marques, O., Porto, G., Rêma, A., Faria, F., Cruz Paula, A., Gomez-Lazaro, M., Silva, P., Martins da Silva, B., Lopes, C., Local iron homeostasis in the breast ductal carcinoma microenvironment. BMC Cancer, 16, 2016, 187, 10.1186/s12885-016-2228-y.
29. [29] Alkhateeb, A.A., Han, B., Connor, J.R., Ferritin stimulates breast cancer cells through an iron-independent mechanism and is localized within tumor-associated macrophages. Breast Cancer Res. Treat. 137:3 (2013), 733–744, 10.1007/s10549-012-2405-x.
30. [30] Donovan, A., Lima, C.A., Pinkus, J.L., Pinkus, G.S., Zon, L.I., Robine, S., Andrews, N.C., The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. Cell Metab., 2005, 191–200.
31. [31] De Domenico, I., Ward, D.M., Langelier, C., Vaughn, M.B., Nemeth, E., Sundquist, W.I., Ganz, T., Musci, G., Kaplan, J., The molecular mechanism of hepcidin-mediated ferroportin down-regulation. Mol. Biol. Cell 18:7 (2007), 2569–2578, 10.1091/mbc.e07-01-0060.
32. [32] Gardenghi, S., Ramos, P., Marongiu, M.F., Melchiori, L., Breda, L., Guy, E., Muirhead, K., Rao, N., Roy, C.N., Andrews, N.C., Nemeth, E., Follenzi, A., An, X., Mohandas, N., Ginzburg, Y., Rachmilewitz, E.A., Giardina, P.J., Grady, R.W., Rivella, S., Hepcidin as a therapeutic tool to limit iron overload and improve anemia in beta-thalassemic mice. J. Clin. Invest. 120:12 (2010), 4466–4477, 10.1172/JCI41717.
33. [33] Rishi, G., Wallace, D.F., Subramaniam, V.N., Hepcidin: regulation of the master iron regulator. Biosci. Rep., 35(3), 2015, 10.1042/bsr20150014 (pii: e00192).
34. [34] Wessling-Resnick, M., Iron homeostasis and the inflammatory response. Annu. Rev. Nutr. 30 (2010), 105–122, 10.1146/annurev.nutr.012809.104804.
35. [35] Poli, M., Asperti, M., Ruzzenenti, P., Regoni, M., Arosio, P., Hepcidin antagonists for potential treatments of disorders with hepcidin excess. Front. Pharmacol., 5, 2014, 86, 10.3389/fphar.2014.00086.
36. [36] Tlsty, T.D., Coussens, L.M., Tumor stroma and regulation of cancer development. Annu. Rev. Pathol. 1 (2006), 119–150, 10.1146/annurev.pathol.1.110304.100224.
37. [37] Quail, D.F., Joyce, J.A., Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 19:11 (2013), 1423–1437, 10.1038/nm.3394.
38. [38] Smith, H.A., Kang, Y., The metastasis-promoting roles of tumor-associated immune cells. J. Mol. Med. (Berl.) 91:4 (2013), 411–429, 10.1007/s00109-013-1021-5.
39. [39] Ma, X.J., Dahiya, S., Richardson, E., Erlander, M., Sgroi, D.C., Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res., 11(1), 2009, R7, 10.1186/bcr2222.
40. [40] Neve, R.M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F.L., Fevr, T., Clark, L., Bayani, N., Coppe, J.P., Tong, F., Speed, T., Spellman, P.T., DeVries, S., Lapuk, A., Wang, N.J., Kuo, W.L., Stilwell, J.L., Pinkel, D., Albertson, D.G., Waldman, F.M., McCormick, F., Dickson, R.B., Johnson, M.D., Lippman, M., Ethier, S., Gazdar, A., Gray, J.W., A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10:6 (2006), 515–527, 10.1016/j.ccr.2006.10.008.
41. [41] Weigelt, B., Mackay, A., A'Hern, R., Natrajan, R., Tan, D.S., Dowsett, M., Ashworth, A., Reis-Filho, J.S., Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol. 11:4 (2010), 339–349, 10.1016/s1470-2045(10)70008-5.
42. [42] Allavena, P., Sica, A., Solinas, G., Porta, C., Mantovani, A., The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit. Rev. Oncol. Hematol. 66:1 (2008), 1–9, 10.1016/j.critrevonc.2007.07.004.
43. [43] Coussens, L.M., Werb, Z., Inflammation and cancer. Nature 420:6917 (2002), 860–867, 10.1038/nature01322.
44. [44] Gomes, F.G., Nedel, F., Alves, A.M., Nor, J.E., Tarquinio, S.B., Tumor angiogenesis and lymphangiogenesis: tumor/endothelial crosstalk and cellular/microenvironmental signaling mechanisms. Life Sci. 92:2 (2013), 101–107, 10.1016/j.lfs.2012.10.008.
45. [45] Hu, Y., He, M.Y., Zhu, L.F., Yang, C.C., Zhou, M.L., Wang, Q., Zhang, W., Zheng, Y.Y., Wang, D.M., Xu, Z.Q., Wu, Y.N., Liu, L.K., Tumor-associated macrophages correlate with the clinicopathological features and poor outcomes via inducing epithelial to mesenchymal transition in oral squamous cell carcinoma. J. Exp. Clin. Cancer Res., 35, 2016, 12, 10.1186/s13046-015-0281-z.
46. [46] Zhang, Q.W., Liu, L., Gong, C.Y., Shi, H.S., Zeng, Y.H., Wang, X.Z., Zhao, Y.W., Wei, Y.Q., Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. PLoS One, 7(12), 2012, e50946, 10.1371/journal.pone.0050946.
47. [47] Qian, B.Z., Pollard, J.W., Macrophage diversity enhances tumor progression and metastasis. Cell 141:1 (2010), 39–51, 10.1016/j.cell.2010.03.014.
48. [48] Tsutsui, S., Yasuda, K., Suzuki, K., Tahara, K., Higashi, H., Era, S., Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density. Oncol. Rep. 14:2 (2005), 425–431, 10.3892/or.14.2.425.
49. [49] Leek, R.D., Landers, R.J., Harris, A.L., Lewis, C.E., Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Br. J. Cancer 79:5–6 (1999), 991–995, 10.1038/sj.bjc.6690158.
50. [50] Verjans, E., Noetzel, E., Bektas, N., Schütz, A.K., Lue, H., Lennartz, B., Hartmann, A., Dahl, E., Bernhagen, J., Dual role of macrophage migration inhibitory factor (MIF) in human breast cancer. BMC Cancer, 9, 2009, 230, 10.1186/1471-2407-9-230.
51. [51] Cairo, G., Recalcati, S., Mantovani, A., Locati, M., Iron trafficking and metabolism in macrophages: contribution to the polarized phenotype. Trends Immunol. 32:6 (2011), 241–247, 10.1016/j.it.2011.03.007.
52. [52] Corna, G., Campana, L., Pignatti, E., Castiglioni, A., Tagliafico, E., Bosurgi, L., Campanella, A., Brunelli, S., Manfredi, A.A., Apostoli, P., Silvestri, L., Camaschella, C., Rovere-Querini, P., Polarization dictates iron handling by inflammatory and alternatively activated macrophages. Haematologica 95:11 (2010), 1814–1822, 10.3324/haematol.2010.023879.
53. [53] Muckenthaler, M.U., Rivella, S., Hentze, M.W., Galy, B., A red carpet for iron metabolism. Cell 168:3 (2016), 344–361, 10.1016/j.cell.2016.12.034.
54. [54] Martinez, F.O., Gordon, S., The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep. 6:13 (2014), 6–13, 10.12703/P.
55. [55] Mosser, D.M., Edwards, J.P., Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 8:12 (2008), 958–969, 10.1038/nri2448.
56. [56] Mantovani, A., Allavena, P., Sica, A., Balkwill, F., Cancer-related inflammation. Nature 454:7203 (2008), 436–444, 10.1038/nature07205.
57. [57] Mertens, C., Akam, E.A., Rehwald, C., Brüne, B., Tomat, E., Jung, M., Intracellular iron chelation modulates the macrophage iron phenotype with consequences on tumor progression. PLoS One, 11(11), 2016, e0166164, 10.1371/journal.pone.0166164.
58. [58] Folkman, J., Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285:21 (1971), 1182–1186, 10.1056/nejm197111182852108.
59. [59] Recalcati, S., Locati, M., Cairo, G., Systemic and cellular consequences of macrophage control of iron metabolism. Semin. Immunol. 24:6 (2012), 393–398, 10.1016/j.smim.2013.01.001.
60. [60] Recalcati, S., Locati, M., Marini, A., Santambrogio, P., Zaninotto, F., De Pizzol, M., Zammataro, L., Girelli, D., Cairo, G., Differential regulation of iron homeostasis during human macrophage polarized activation. Exp. Oncol. 40:3 (2010), 824–835, 10.1002/eji.200939889.
61. [61] Freitas, I., Boncompagni, E., Vaccarone, R., Fenoglio, C., Barni, S., Baronzio, G.F., Iron accumulation in mammary tumor suggests a tug of war between tumor and host for the microelement. Anticancer Res. 27:5A (2007), 3059–3065.
62. [62] Franklin, R.A., Liao, W., Sarkar, A., Kim, M.V., Bivona, M.R., Liu, K., Pamer, E.G., Li, M.O., The cellular and molecular origin of tumor-associated macrophages. Science 344:6186 (2014), 921–935, 10.1126/science.1252510.
63. [63] Zou, W., Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 5:4 (2005), 263–274, 10.1038/nrc1586.
64. [64] Gabrilovich, D.I., Ostrand-Rosenberg, S., Bronte, V., Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12:4 (2012), 253–268, 10.1038/nri3175.
65. [65] DeNardo, D.G., Andreu, P., Coussens, L.M., Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. Cancer Metastasis Rev. 29:2 (2010), 309–316, 10.1007/s10555-010-9223-6.
66. [66] Fridman, W.H., Pagès, F., Sautès-Fridman, C., Galon, J., The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 12:4 (2012), 298–306, 10.1038/nrc3245.
67. [67] Seligman, P.A., Kovar, J., Gelfand, E.W., Lymphocyte proliferation is controlled by both iron availability and regulation of iron uptake pathways. Pathobiology 60:1 (1992), 19–26.
68. [68] Weiss, G., Iron and immunity: a double-edged sword. Eur. J. Clin. Invest. 32:Suppl. 1 (2002), 70–78, 10.1046/j.1365-2362.2002.0320s1070.x.
69. [69] Kemp, J.D., Smith, K.M., Kanner, L.J., Gomez, F., Thorson, J.A., Naumann, P.W., Synergistic inhibition of lymphoid tumor growth in vitro by combined treatment with the iron chelator deferoxamine and an immunoglobulin G monoclonal antibody against the transferrin receptor. Blood 76:5 (1990), 991–995.
70. [70] Gray, C.P., Arosio, P., Hersey, P., Heavy chain ferritin activates regulatory T cells by induction of changes in dendritic cells. Blood 99:9 (2002), 3326–3334, 10.1182/blood.V99.9.3326.
71. [71] Fargion, S., Fracanzani, A.L., Brando, B., Arosio, P., Levi, S., Fiorelli, G., Specific binding sites for H-ferritin on human lymphocytes: modulation during cellular proliferation and potential implication in cell growth control. Blood 78:4 (1991), 1056–1061.
72. [72] Gray, C.P., Arosio, P., Hersey, P., Association of increased levels of heavy-chain ferritin with increased CD4+ CD25+ regulatory T-cell levels in patients with melanoma. Clin. Cancer Res. 9:7 (2003), 2551–2559.
73. [73] Flower, D.R., The lipocalin protein family: a role in cell regulation. FEBS Lett. 354:1 (1994), 7–11, 10.1016/0014-5793(94)01078-1.
74. [74] Goetz, D.H., Holmes, M.A., Borregaard, N., Bluhm, M.E., Raymond, K.N., Strong, R.K., The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol. Cell 10:5 (2002), 1033–1043, 10.1016/s1097-2765(02)00708-6.
75. [75] Miethke, M., Marahiel, M.A., Siderophore-based iron acquisition and pathogen control. Microbiol. Mol. Biol. Rev. 71:3 (2007), 413–451, 10.1128/MMBR00012-07.
76. [76] Raymond, K.N., Dertz, E.A., Kim, S.S., Enterobactin: an archetype for microbial iron transport. Proc. Natl. Acad. Sci. U. S. A. 100:7 (2003), 3584–3588, 10.1073/pnas.0630018100.
77. [77] Flo, T.H., Smith, K.D., Sato, S., Rodriguez, D.J., Holmes, M.A., Strong, R.K., Akira, S., Aderem, A., Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature 432:7019 (2004), 917–921, 10.1038/nature03104.
78. [78] Berger, T., Togawa, A., Duncan, G.S., Elia, A.J., You-Ten, A., Wakeham, A., Fong, H.E., Cheung, C.C., Mak, T.W., Lipocalin 2-deficient mice exhibit increased sensitivity to Escherichia coli infection but not to ischemia-reperfusion injury. Proc. Natl. Acad. Sci. U. S. A. 103:6 (2006), 1834–1839, 10.1073/pnas.0510847103.
79. [79] Chan, Y.R., Liu, J.S., Pociask, D.A., Zheng, M., Mietzner, T.A., Berger, T., Mak, T.W., Clifton, M.C., Strong, R.K., Ray, P., Kolls, J.K., Lipocalin 2 is required for pulmonary host defense against Klebsiella infection. J. Immunol. 182:8 (2009), 4947–4956, 10.4049/jimmunol.0803282.
80. [80] Raffatellu, M., George, M.D., Akiyama, Y., Hornsby, M.J., Nuccio, S.P., Paixao, T.A., Butler, B.P., Chu, H., Santos, R.L., Berger, T., Mak, T.W., Tsolis, R.M., Bevins, C.L., Solnick, J.V., Dandekar, S., Bäumler, A.J., Lipocalin-2 resistance confers an advantage to Salmonella enterica serotype Typhimurium for growth and survival in the inflamed intestine. Cell Host Microbe 5:5 (2009), 476–486, 10.1016/j.chom.2009.03.011.
81. [81] Steigedal, M., Marstad, A., Haug, M., Damås, J.K., Strong, R.K., Roberts, P.L., Himpsl, S.D., Stapleton, A., Hooton, T.M., Mobley, H.L., Hawn, T.R., Flo, T.H., Lipocalin 2 imparts selective pressure on bacterial growth in the bladder and is elevated in women with urinary tract infection. J. Immunol. 193:12 (2014), 6081–6089, 10.4049/jimmunol.1401528.
82. [82] Liu, Z., Petersen, R., Devireddy, L., Impaired neutrophil function in 24p3 null mice contributes to enhanced susceptibility to bacterial infections. J. Immunol. 190:9 (2013), 4692–4706, 10.4049/jimmunol.1202411.
83. [83] Liu, Z., Reba, S., Chen, W.D., Porwal, S.K., Boom, W.H., Petersen, R.B., Rojas, R., Viswanathan, R., Devireddy, L., Regulation of mammalian siderophore 2,5-DHBA in the innate immune response to infection. J. Exp. Med. 211:6 (2014), 1197–1213, 10.1084/jem.20132629.
84. [84] Li, J.Y., Ram, G., Gast, K., Chen, X., Barasch, K., Mori, K., Schmidt-Ott, K., Wang, J., Kuo, H.C., Savage-Dunn, C., Garrick, M.D., Barasch, J., Detection of intracellular iron by its regulatory effect. Am. J. Physiol. Cell Physiol. 287:6 (2004), C1547–C1559, 10.1152/ajpcell.00260.2004.
85. [85] Yang, J., Goetz, D., Li, J.Y., Wang, W., Mori, K., Setlik, D., Du, T., Erdjument-Bromage, H., Tempst, P., Strong, R., Barasch, J., An iron delivery pathway mediated by a lipocalin. Mol. Cell 10:5 (2002), 1045–1056, 10.1016/s1097-2765(02)00710-4.
86. [86] Devarajan, P., Mishra, J., Supavekin, S., Patterson, L.T., Steven Potter, S., Gene expression in early ischemic renal injury: clues towards pathogenesis, biomarker discovery, and novel therapeutics. Mol. Genet. Metab. 80:4 (2003), 365–376, 10.1016/j.ymgme.2003.09.012.
87. [87] Mishra, J., Ma, Q., Prada, A., Mitsnefes, M., Zahedi, K., Yang, J., Barasch, J., Devarajan, P., Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J. Am. Soc. Nephrol. 14:10 (2003), 2534–2543, 10.1097/01.ASN.0000088027.54400.C6.
88. [88] Mori, K., Lee, H.T., Rapoport, D., Drexler, I.R., Foster, K., Yang, J., Schmidt-Ott, K.M., Chen, X., Li, J.Y., Weiss, S., Mishra, J., Cheema, F.H., Markowitz, G., Suganami, T., Sawai, K., Mukoyama, M., Kunis, C., D'Agati, V., Devarajan, P., Barasch, J., Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J. Clin. Invest. 115:3 (2005), 610–621, 10.1172/JCI23056.
89. [89] Kanda, J., Mori, K., Kawabata, H., Kuwabara, T., Mori, K.P., Imamaki, H., Kasahara, M., Yokoi, H., Mizumoto, C., Thoennissen, N.H., Koeffler, H.P., Barasch, J., Takaori-Kondo, A., Mukoyama, M., Nakao, K., An AKI biomarker lipocalin 2 in the blood derives from the kidney in renal injury but from neutrophils in normal and infected conditions. Clin. Exp. Nephrol. 19:1 (2015), 99–106, 10.1007/s10157-014-0952-7.
90. [90] Virzì, G.M., Clementi, A., de Cal, M., Cruz, D.N., Ronco, C., Genomics and biological activity of neutrophil gelatinase-associated lipocalin in several clinical settings. Blood Purif. 35:1–3 (2013), 139–143, 10.1159/000346100.
91. [91] Borregaard, N., Cowland, J.B., Neutrophil gelatinase-associated lipocalin, a siderophore-binding eukaryotic protein. Biometals 19:2 (2006), 211–225, 10.1007/s10534-005-3251-7.
92. [92] Vinuesa, E., Sola, A., Jung, M., Alfaro, V., Hotter, G., Lipocalin-2-induced renal regeneration depends on cytokines. Am. J. Physiol. Renal. Physiol. 295:5 (2008), F1554–F1562, 10.1152/ajprenal.90250.2008.
93. [93] Bauer, M., Eickhoff, J.C., Gould, M.N., Mundhenke, C., Maass, N., Friedl, A., Neutrophil gelatinase-associated lipocalin (NGAL) is a predictor of poor prognosis in human primary breast cancer. Breast Cancer Res. Treat. 108:3 (2008), 389–397, 10.1007/s10549-007-9619-3.
94. [94] Mannelqvist, M., Stefansson, I.M., Wik, E., Kusonmano, K., Raeder, M.B., Øyan, A.M., Kalland, K.H., Moses, M.A., Salvesen, H.B., Akslen, L.A., Lipocalin 2 expression is associated with aggressive features of endometrial cancer. BMC Cancer, 12, 2012, 169, 10.1186/1471-2407-12-169.
95. [95] Pitteri, S.J., Faca, V.M., Kelly-Spratt, K.S., Kasarda, A.E., Wang, H., Zhang, Q., Newcomb, L., Krasnoselsky, A., Paczesny, S., Choi, G., Fitzgibbon, M., McIntosh, M.W., Kemp, C.J., Hanash, S.M., Plasma proteome profiling of a mouse model of breast cancer identifies a set of up-regulated proteins in common with human breast cancer cells. J. Proteome Res. 7:4 (2008), 1481–1489, 10.1021/pr7007994.
96. [96] Berger, T., Cheung, C.C., Elia, A.J., Mak, T.W., Disruption of the Lcn2 gene in mice suppresses primary mammary tumor formation but does not decrease lung metastasis. Proc. Natl. Acad. Sci. U. S. A. 107:7 (2010), 2995–3000, 10.1073/pnas.1000101107.
97. [97] Ören, B., Urosevic, J., Mertens, C., Mora, J., Guiu, M., Gomis, R.R., Weigert, A., Schmid, T., Grein, S., Brüne, B., Jung, M., Tumour stroma-derived lipocalin-2 promotes breast cancer metastasis. J. Pathol. 239:3 (2016), 274–285, 10.1002/path.4724.
98. [98] Leng, X., Ding, T., Lin, H., Wang, Y., Hu, L., Hu, J., Feig, B., Zhang, W., Pusztai, L., Symmans, W.F., Wu, Y., Arlinghaus, R.B., Inhibition of lipocalin 2 impairs breast tumorigenesis and metastasis. Cancer Res. 69:22 (2009), 8579–8584, 10.1158/0008-5472.CAN-09-1934.
99. [99] Shi, H., Gu, Y., Yang, J., Xu, L., Mi, W., Yu, W., Lipocalin 2 promotes lung metastasis of murine breast cancer cells. J. Exp. Clin. Cancer Res., 27, 2008, 83, 10.1186/1756-9966-27-83.
100. [100] Kjeldsen, L., Johnsen, A.H., Sengeløv, H., Borregaard, N., Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J. Biol. Chem. 268:14 (1993), 10425–10432.
101. [101] Rudd, P.M., Mattu, T.S., Masure, S., Bratt, T., Van den Steen, P.E., Wormald, M.R., Küster, B., Harvey, D.J., Borregaard, N., Van Damme, J., Dwek, R.A., Opdenakker, G., Glycosylation of natural human neutrophil gelatinase B and neutrophil gelatinase B-associated lipocalin. Biochemistry 38:42 (1999), 13937–13950, 10.1021/bi991162e.
102. [102] Yan, L., Borregaard, N., Kjeldsen, L., Moses, M.A., The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J. Biol. Chem. 276:40 (2001), 37258–37265, 10.1074/jbc.M106089200.
103. [103] Kubben, F.J., Sier, C.F., Hawinkels, L.J., Tschesche, H., van Duijn, W., Zuidwijk, K., van der Reijden, J.J., Hanemaaijer, R., Griffioen, G., Lamers, C.B., Verspaget, H.W., Clinical evidence for a protective role of lipocalin-2 against MMP-9 autodegradation and the impact for gastric cancer. Eur. J. Cancer 43:12 (2007), 1869–1876, 10.1016/j.ejca.2007.05.013.
104. [104] Deryugina, E.I., Quigley, J.P., Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 25:1 (2006), 9–34, 10.1007/s10555-006-7886-9.
105. [105] Fernández, C.A., Yan, L., Louis, G., Yang, J., Kutok, J.L., Moses, M.A., The matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients. Clin. Cancer Res. 11:15 (2005), 5390–5395, 10.1158/1078-0432.CCR-04-2391.
106. [106] Mira, E., Lacalle, R.A., Buesa, J.M., de Buitrago, G.G., Jiménez-Baranda, S., Gómez-Moutón, C., Martínez, A.C., Mañes, S., Secreted MMP9 promotes angiogenesis more efficiently than constitutive active MMP9 bound to the tumor cell surface. J. Cell Sci. 117:Pt 9 (2004), 1847–1857, 10.1242/jcs.01035.
107. [107] Nuntagowat, C., Leelawat, K., Tohtong, R., NGAL knockdown by siRNA in human cholangiocarcinoma cells suppressed invasion by reducing NGAL/MMP-9 complex formation. Clin. Exp. Metastasis 27:5 (2010), 295–305, 10.1007/s10585-010-9327-y.
108. [108] Yang, J., Bielenberg, D.R., Rodig, S.J., Doiron, R., Clifton, M.C., Kung, A.L., Strong, R.K., Zurakowski, D., Moses, M.A., Lipocalin 2 promotes breast cancer progression. Proc. Natl. Acad. Sci. U. S. A. 106:10 (2009), 3913–3918, 10.1073/pnas.0810617106.
109. [109] Jung, M., Ören, B., Mora, J., Mertens, C., Dziumbla, S., Popp, R., Weigert, A., Grossmann, N., Fleming, I., Brüne, B., Lipocalin 2 from macrophages stimulated by tumor cell-derived sphingosine 1-phosphate promotes lymphangiogenesis and tumor metastasis. Sci. Signal., 9(434), 2016, ra64, 10.1126/scisignal.aaf3241.
110. [110] Devireddy, L.R., Gazin, C., Zhu, X., Green, M.R., A cell-surface receptor for lipocalin 24p3 selectively mediates apoptosis and iron uptake. Cell 123:7 (2005), 1293–1305, 10.1016/j.cell.2005.10.027.
111. [111] Huggenvik, J.I., Craven, C.M., Idzerda, R.L., Bernstein, S., Kaplan, J., McKnight, G.S., A splicing defect in the mouse transferrin gene leads to congenital atransferrinemia. Blood 74:1 (1989), 482–486.
112. [112] Trenor, C.C. 3rd, Campagna, D.R., Sellers, V.M., Andrews, N.C., Fleming, M.D., The molecular defect in hypotransferrinemic mice. Blood 96:3 (2000), 1113–1118.
113. [113] Sola, A., Weigert, A., Jung, M., Vinuesa, E., Brecht, K., Weis, N., Brüne, B., Borregaard, N., Hotter, G., Sphingosine-1-phosphate signalling induces the production of Lcn-2 by macrophages to promote kidney regeneration. J. Pathol. 225:4 (2011), 597–608, 10.1002/path.2982.
114. [114] Jung, M., Weigert, A., Tausendschön, M., Mora, J., Ören, B., Sola, A., Hotter, G., Muta, T., Brüne, B., Interleukin-10-induced neutrophil gelatinase-associated lipocalin production in macrophages with consequences for tumor growth. Mol. Cell. Biol. 32:19 (2012), 3938–3948, 10.1128/MCB.00413-12.
115. [115] Gheorgheosu, D., Jung, M., Ören, B., Schmid, T., Dehelean, C., Muntean, D., Brüne, B., Betulinic acid suppresses NGAL-induced epithelial-to-mesenchymal transition in melanoma. Biol. Chem. 394:6 (2013), 773–781, 10.1515/hsz-2013-0106.
116. [116] Corbin, J.L., Bulen, W.A., isolation and identification of 2,3-dihydroxybenzoic acid and 2-N,6-N-di-92,3-dihydroxybenzoyl)-L-lysine formed by iron-deficient Azotobacter vinelandii. Biochemistry 8:3 (1969), 757–762.
117. [117] Gibson, F., Magrath, D.I., The isolation and characterization of a hydroxamic acid (aerobactin) formed by Aerobacter aerogenes 62-I. Biochim. Biophys. Acta 192:2 (1969), 175–184.
118. [118] Pollack, J.R., Neilands, J.B., an iron transport compound from Salmonella typhimurium. Biochem. Biophys. Res. Commun. 38:5 (1970), 989–992, 10.1016/0006-291x(70)90819-3.
119. [119] Ratledge, C., Dover, L.G., Iron metabolism in pathogenic bacteria. Annu. Rev. Microbiol. 54 (2000), 881–941, 10.1146/annurev.micro.54.1.881.
120. [120] Drechsel, H., Winkelmann, G., Iron chelation and siderophores. Winkelmann, G., Carrano, C.J., (eds.) Transition Metals in Microbial Metabolism, 1997, Harwood Academic Publishers, 1–50.
121. [121] Aisen, P., Listowsky, I., Iron transport and storage proteins. Annu. Rev. Biochem. 49 (1980), 357–393, 10.1146/annurev.bi.49.070180.002041.
122. [122] Pietrangelo, A., Mechanism of iron toxicity. Adv. Exp. Med. Biol. 509 (2002), 19–43, 10.1007/978-1-4615-0593-8_2.
123. [123] Saha, M., Sarkar, S., Sarkar, B., Sharma, B.K., Bhattacharjee, S., Tribedi, P., Microbial siderophores and their potential applications: a review. Environ. Sci. Pollut. Res. Int. 23:5 (2016), 3984–3999, 10.1007/s11356-015-4294-0.
124. [124] Hoette, T.M., Abergel, R.J., Xu, J., Strong, R.K., Raymond, K.N., The role of electrostatics in siderophore recognition by the immunoprotein Siderocalin. J. Am. Chem. Soc. 130:51 (2008), 17584–17592, 10.1021/ja8074665.
125. [125] Devireddy, L.R., Hart, D.O., Goetz, D.H., Green, M.R., A mammalian siderophore synthesized by an enzyme with a bacterial homolog involved in enterobactin production. Cell 141:6 (2010), 1006–1017, 10.1016/j.cell.2010.04.040.
126. [126] Abergel, R.J., Warner, J.A., Shuh, D.K., Raymond, K.N., Enterobactin protonation and iron release: structural characterization of the salicylate coordination shift in ferric enterobactin. J. Am. Chem. Soc. 128:27 (2006), 8920–8931, 10.1021/ja062046j.
127. [127] Correnti, C., Richardson, V., Sia, A.K., Bandaranayake, A.D., Ruiz, M., Suryo Rahmanto, Y., Kovačević, Ž., Clifton, M.C., Holmes, M.A., Kaiser, B.K., Barasch, J., Raymond, K.N., Richardson, D.R., Strong, R.K., Siderocalin/Lcn2/NGAL/24p3 does not drive apoptosis through gentisic acid mediated iron withdrawal in hematopoietic cell lines. PLoS One, 7(8), 2012, e43696, 10.1371/journal.pone.0043696.
128. [128] Kante, A., Cherkaoui Malki, M., Coquard, C., Latruffe, N., Metabolic control of the expression of mitochondrial D-beta-hydroxybutyrate dehydrogenase, a ketone body converting enzyme. Biochim. Biophys. Acta 1033:3 (1990), 291–297, 10.1016/0304-4165(90)90136-k.
129. [129] Guo, K., Lukacik, P., Papagrigoriou, E., Meier, M., Lee, W.H., Adamski, J., Oppermann, U., Characterization of human DHRS6, an orphan short chain dehydrogenase/reductase enzyme: a novel, cytosolic type 2 R-beta-hydroxybutyrate dehydrogenase. J. Biol. Chem. 281:15 (2006), 10291–10297, 10.1074/jbc.m511346200.
130. [130] Oppermann, U., Filling, C., Hult, M., Shafqat, N., Wu, X., Lindh, M., Shafqat, J., Nordling, E., Kallberg, Y., Persson, B., Jörnvall, H., Short-chain dehydrogenases/reductases (SDR): the 2002 update. Chem. Biol. Interact. 143–144 (2003), 247–253, 10.1016/s0009-2797(02)00164-3.
131. [131] Liu, Z., Ciocea, A., Devireddy, L., Endogenous siderophore 2, 5-dihydroxybenzoic acid deficiency promotes anemia and splenic iron overload in mice. Mol. Cell. Biol. 34:13 (2014), 2533–2546, 10.1128/MCB.00231-14.
132. [132] Liu, Z., Velpula, K.K., Devireddy, L., 3-Hydroxybutyrate dehydrogenase-2 and ferritin-H synergistically regulate intracellular iron. FEBS J. 281:10 (2014), 2410–2421, 10.1111/febs.12794.
133. [133] Gulec, S., Anderson, G.J., Collins, J.F., Mechanistic and regulatory aspects of intestinal iron absorption. Am. J. Physiol. Gastrointest. Liver Physiol. 307:4 (2014), G397–G409, 10.1152/ajpgi.00348.2013.
134. [134] Finn, A.V., Nakano, M., Polavarapu, R., Karmali, V., Saeed, O., Zhao, X., Yazdani, S., Otsuka, F., Davis, T., Habib, A., Narula, J., Kolodgie, F.D., Virmani, R., Hemoglobin directs macrophage differentiation and prevents foam cell formation in human atherosclerotic plaques. J. Am. Coll. Cardiol. 59:2 (2012), 166–177, 10.1016/j.jacc.2011.10.852.
135. [135] Saeed, O., Otsuka, F., Polavarapu, R., Karmali, V., Weiss, D., Davis, T., Rostad, B., Pachura, K., Adams, L., Elliott, J., Taylor, W.R., Narula, J., Kolodgie, F., Virmani, R., Hong, C.C., Finn, A.V., Pharmacological suppression of hepcidin increases macrophage cholesterol efflux and reduces foam cell formation and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 32:2 (2012), 299–307, 10.1161/atvbaha.111.240101.
136. [136] Ananth, S., Gnana-Prakasam, J.P., Bhutia, Y.D., Veeranan-Karmegam, R., Martin, P.M., Smith, S.B., Ganapathy, V., Regulation of the cholesterol efflux transporters ABCA1 and ABCG1 in retina in hemochromatosis and by the endogenous siderophore 2,5-dihydroxybenzoic acid. Biochim. Biophys. Acta 1842:4 (2014), 603–612, 10.1016/j.bbadis.2014.01.010.
137. [137] Krewulak, K.D., Vogel, H.J., Structural biology of bacterial iron uptake. Biochim. Biophys. Acta 1778:9 (2008), 1781–1804, 10.1016/j.bbamem.2007.07.026.
138. [138] Hatcher, H.C., Singh, R.N., Torti, F.M., Torti, S.V., Synthetic and natural iron chelators: therapeutic potential and clinical use. Future Med. Chem. 1:9 (2009), 1643–1670, 10.4155/fmc.09.121.
139. [139] Heath, J.L., Weiss, J.M., Lavau, C.P., Wechsler, D.S., Iron deprivation in cancer-potential therapeutic implications. Nutrients 5:8 (2013), 2836–2859, 10.3390/nu5082836.
140. [140] Torti, S.V., Torti, F.M., Iron and cancer: more ore to be mined. Nat. Rev. Cancer 13:5 (2013), 342–355, 10.1038/nrc3495.
141. [141] Power Coombs, M.R., Grant, T., Greenshields, A.L., Arsenault, D.J., Holbein, B.E., Hoskin, D.W., Inhibitory effect of iron withdrawal by chelation on the growth of human and murine mammary carcinoma and fibrosarcoma cells. Exp. Mol. Pathol. 99:2 (2015), 262–270, 10.1016/j.yexmp.2015.07.008.
142. [142] Hann, H.W., Stahlhut, M.W., Rubin, R., Maddrey, W.C., Antitumor effect of deferoxamine on human hepatocellular carcinoma growing in athymic nude mice. Cancer 70:8 (1992), 2051–2056, 10.1002/1097-0142(19921015)70:8<2051:AID-CNCR2820700806>3.0.CO;2-1.
143. [143] Hoke, E.M., Maylock, C.A., Shacter, E., Desferal inhibits breast tumor growth and does not interfere with the tumoricidal activity of doxorubicin. Free Radic. Biol. Med. 39:3 (2005), 403–411, 10.1016/j.freeradbiomed.2005.03.029.
144. [144] Wang, F., Elliott, R.L., Head, J.F., Inhibitory effect of deferoxamine mesylate and low iron diet on the 13762NF rat mammary adenocarcinoma. Anticancer Res. 19:1A (1999), 445–450.
145. [145] Kalinowski, D.S., Richardson, D.R., The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol. Rev. 57:4 (2005), 547–583, 10.1124/pr.57.4.2.
146. [146] Blatt, J., Boegel, F., Hedlund, B.E., Arena, V.C., Shadduck, R.K., Failure to alter the course of acute myelogenous leukemia in the rat with subcutaneous deferoxamine. Leuk. Res. 15:5 (1991), 391–394, 10.1016/0145-2126(91)90015-l.
147. [147] Kratz, F., Müller, I.A., Ryppa, C., Warnecke, A., Prodrug strategies in anticancer chemotherapy. ChemMedChem 3:1 (2008), 20–53, 10.1002/cmdc.200700159.
148. [148] Akam, E.A., Chang, T.M., Astashkin, A.V., Tomat, E., Intracellular reduction/activation of a disulfide switch in thiosemicarbazone iron chelators. Metallomics 6:10 (2014), 1905–1912, 10.1039/c4mt00153b.
149. [149] Chang, T.M., Tomat, E., Disulfide/thiol switches in thiosemicarbazone ligands for redox-directed iron chelation. Dalton Trans. 42:22 (2013), 7846–7849, 10.1039/c3dt50824b.
150. [150] Gamcsik, M.P., Kasibhatla, M.S., Teeter, S.D., Colvin, O.M., Glutathione levels in human tumors. Biomarkers 17:8 (2012), 671–691, 10.3109/1354750x.2012.715672.
151. [151] Younes, M., Lechago, L.V., Lechago, J., Overexpression of the human erythrocyte glucose transporter occurs as a late event in human colorectal carcinogenesis and is associated with an increased incidence of lymph node metastases. Clin. Cancer Res. 2:7 (1996), 1151–1154.
152. [152] Akam, E.A., Tomat, E., Targeting iron in colon cancer via glycoconjugation of thiosemicarbazone prochelators. Bioconjugate Chem. 27:8 (2016), 1807–1812, 10.1021/acs.bioconjchem.6b00332.